Gatehouse Bio utilizes its Code-Breaker™ platform to decode small RNA (sRNA) landscapes and design precision oligonucleotide therapeutics for diseases such as pulmonary, cardiac, neurological, and autoimmune disorders. By leveraging AI, the company aims to identify RNA codes that contribute to disease mechanisms, facilitating the development of targeted therapies that improve patient outcomes.
Funding
$5.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including pulmonary, cardiac, neurological, and autoimmune disorders, are driven by complex RNA interactions that are difficult to decipher and target with traditional therapies. Identifying the specific small RNA (sRNA) codes that contribute to disease mechanisms remains a significant challenge. This lack of understanding hinders the development of effective, targeted treatments.
Solution
Gatehouse Bio utilizes its Code-Breaker™ platform, an AI-driven technology, to decode the landscape of small RNAs (sRNAs) and design precision oligonucleotide therapeutics. The platform identifies RNA codes that drive disease, enabling the development of biomarker-guided therapies. By understanding the complex mRNA :: sRNA activity relationships, Gatehouse Bio aims to create targeted treatments for a range of diseases. The company is focused on developing its lead targets into therapies for pulmonary, cardiac, neurological, and autoimmune diseases.
Target Audience
Gatehouse Bio's primary customers are researchers discovering biomarkers, those hunting for novel drug targets, and those exploring disease to better understand biology, as well as potential business development partners seeking to co-develop precision medicines.
Features
- Code-Breaker™ platform uses AI to decode small RNA (sRNA) landscapes.
- Designs biomarker-guided precision oligonucleotide therapeutics.
- Identifies RNA codes that contribute to disease mechanisms.
- Focuses on developing therapies for pulmonary, cardiac, neurological, and autoimmune diseases.